Marczuk Natalia, Cecerska-Heryć Elżbieta, Jesionowska Anna, Dołęgowska Barbara
Department of Laboratory Diagnostics and Molecular Medicine, Pomeranian Medical University of Szczecin, Poland.
Department of Biochemistry and Medical Chemistry, Pomeranian Medical University of Szczecin, Poland.
Postepy Hig Med Dosw (Online). 2016 Sep 26;70(0):981-988. doi: 10.5604/17322693.1220082.
Adropin is a peptide hormone that was discovered in 2008 by Kumar et al. This protein consists of 76 amino acids, and it was originally described as a secreted peptide, with residues 1-33 encoding a secretory signal peptide sequence. The amino acid sequence of this protein in humans, mice and rats is identical. While our knowledge of the exact physiological roles of this poorly understood peptide continues to evolve, recent data suggest a role in energy homeostasis and the control of glucose and fatty acid metabolism. This protein is encoded by the Enho gene, which is expressed primarily in the liver and the central nervous system. The regulation of adropin secretion is controversial. Adropin immunoreactivity has been reported by several laboratories in the circulation of humans, non-human primates and rodents. However, more recently it has been suggested that adropin is a membrane-bound protein that modulates cell-cell communication. Moreover, adropin has been detected in various tissues and body fluids, such as brain, cerebellum, liver, kidney, heart, pancreas, small intestine, endothelial cells, colostrum, cheese whey and milk. The protein level, as shown by previous research, changes in various physiological and pathophysiological conditions. Adropin is involved in carbohydrate-lipid metabolism, metabolic diseases, central nervous system function, endothelial function and cardiovascular disease. The knowledge of this interesting protein, its exact role and mechanism of action is insufficient. This article provides an overview of the existing literature about the role of adropin, both in physiological and pathophysiological conditions.
促泌素是一种肽类激素,于2008年由库马尔等人发现。这种蛋白质由76个氨基酸组成,最初被描述为一种分泌肽,其1 - 33位残基编码一个分泌信号肽序列。该蛋白质在人类、小鼠和大鼠中的氨基酸序列是相同的。尽管我们对这种了解甚少的肽的确切生理作用的认识仍在不断发展,但最近的数据表明它在能量稳态以及葡萄糖和脂肪酸代谢的控制中发挥作用。这种蛋白质由Enho基因编码,该基因主要在肝脏和中枢神经系统中表达。促泌素分泌的调节存在争议。几个实验室已报道在人类、非人灵长类动物和啮齿动物的循环系统中存在促泌素免疫反应性。然而,最近有人提出促泌素是一种膜结合蛋白,可调节细胞间通讯。此外,在各种组织和体液中都检测到了促泌素,如脑、小脑、肝脏、肾脏、心脏、胰腺、小肠、内皮细胞、初乳、干酪乳清和牛奶。如先前研究所表明的,蛋白质水平在各种生理和病理生理条件下会发生变化。促泌素参与碳水化合物 - 脂质代谢、代谢性疾病、中枢神经系统功能、内皮功能和心血管疾病。关于这种有趣蛋白质的确切作用及其作用机制的了解还不够充分。本文概述了有关促泌素在生理和病理生理条件下作用的现有文献。